Transcranial Magnetic Stimulation (TMS), a safe, non-invasive type of brain stimulation, was approved by the FDA for the treatment of depression in 2008, and is now clinically available for the treatment of adults who have not been helped by antidepressant medications. Recently, FDA cleared TMS for use in patients with obsessive-compulsive disorder, if given immediately […] Read more…
Abstract Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy, vagus nerve stimulation, direct cortical stimulation, and deep brain stimulation among others. […] Read more…
Mark S. George, Joseph J. Taylor, and E. Baron Shor INTRODUCTION Transcranial magnetic stimulation (TMS) is perhaps the most popular of the new brain stimulation techniques because its clinical effects are produced without the need for a craniotomy [as with deep brain stimulation (DBS)] or seizure induction [as with electroconvulsive therapy (ECT)]. As a focal, […] Read more…
Abstract INTRODUCTION: Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. Transcranial magnetic stimulation (TMS) is a US Food and Drug Administration-approved treatment for major depressive disorder (MDD) in patients who have not responded to […] Read more…